Literature DB >> 11166738

Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias.

J M Van Opstal1, J D Leunissen, H J Wellens, M A Vos.   

Abstract

Torsade de Pointes arrhythmias are a feared proarrhythmic effect of (antiarrhythmic) drugs. In dogs with chronic complete AV-block bradycardia-induced volume overload leads to electrical remodeling, which includes increased susceptibility to drug-induced Torsade de Pointes arrhythmias. The IKr channel blocker, dofetilide (Tikosyn, 0.025 mg/kg/5 min), and the less specific ion channel blocker, azimilide (5 mg/kg/5 min), were compared in nine anesthetized dogs at 4 and 6 weeks of AV-block in a randomized cross-over design. Dosages were based on our own dose-dependence studies and on anti-arrhythmic dosages reported in the literature. Monophasic action potential catheters were placed endocardially in both the left and right ventricle to measure action potential duration, visualize early afterdepolarizations, and to assess interventricular dispersion of repolarization (i.e. left ventricular monophasic action potential duration (at 100%) minus right ventricular monophasic action potential duration (at 100%). Cycle length of idioventricular rhythm, QT-time and the occurrence of drug-induced Torsade de Pointes arrhythmias were determined using the surface electrocardiogram (ECG). Before drug administration, the electrophysiological parameters were identical at 4 and 6 weeks. Both azimilide and dofetilide increased monophasic action potential duration, cycle length of idioventricular rhythm, and QT-time. Dissimilar lengthening of left ventricular and right ventricular monophasic action potential duration increased the interventricular dispersion significantly from 55 to 110 ms for both drugs. All dogs had early afterdepolarizations, while, in the majority, ectopic ventricular beats developed (dofetilide 8/9 and azimilide 7/9). Torsade de Pointes arrhythmias incidence was comparable for dofetilide (6/9) and azimilide (5/9). In conclusion, azimilide and dofetilide show similar electrophysiological and proarrhythmic effects in our canine model with a high incidence of Torsade de Pointes arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11166738     DOI: 10.1016/s0014-2999(00)00943-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Einthoven Dissertation Prizes 2002.

Authors: 
Journal:  Neth Heart J       Date:  2003-04       Impact factor: 2.380

2.  Torsades de pointes during complete atrioventricular block: Genetic factors and electrocardiogram correlates.

Authors:  Rajesh N Subbiah; Michael H Gollob; Lorne J Gula; Robert W Davies; Peter Leong-Sit; Allan C Skanes; Raymond Yee; George J Klein; Andrew D Krahn
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

3.  Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes.

Authors:  Elke Detre; Morten B Thomsen; Jet D Beekman; Karl-Uwe Petersen; Marc A Vos
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

4.  Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.

Authors:  L Nalos; R Varkevisser; M K B Jonsson; M J C Houtman; J D Beekman; R van der Nagel; M B Thomsen; G Duker; P Sartipy; T P de Boer; M Peschar; M B Rook; T A B van Veen; M A G van der Heyden; M A Vos
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  The JT-area indicates dispersion of repolarization in dogs with atrioventricular block.

Authors:  Jurren M van Opstal; S Cora Verduyn; Stephan K G Winckels; Hendrik M Leerssen; Jet D M Leunissen; Hein J J Wellens; Marc A Vos
Journal:  J Interv Card Electrophysiol       Date:  2002-06       Impact factor: 1.900

Review 6.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 7.  Drug-induced torsades de pointes and implications for drug development.

Authors:  Robert R Fenichel; Marek Malik; Charles Antzelevitch; Michael Sanguinetti; Dan M Roden; Silvia G Priori; Jeremy N Ruskin; Raymond J Lipicky; Louis R Cantilena
Journal:  J Cardiovasc Electrophysiol       Date:  2004-04

Review 8.  Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.

Authors:  M A Vos
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

9.  The electromechanical window is no better than QT prolongation to assess risk of Torsade de Pointes in the complete atrioventricular block model in dogs.

Authors:  T R G Stams; V J A Bourgonje; H D M Beekman; M Schoenmakers; R van der Nagel; P Oosterhoff; J M van Opstal; M A Vos
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

10.  Safety of the novel atrial-selective K+-channel blocker AVE0118 in experimental heart failure.

Authors:  H-J Schneider; O Husser; M Rihm; S Fredersdorf; C Birner; S Dhein; F Muders; A Jeron; H Goegelein; G A Riegger; A Luchner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.